

Sandoz staff copy  
Not for distribution

LSD 16

Lancet 262, 950 (1952).

# INFLUENCE OF ORGANIC PHOSPHATES ON TUBERCULIN SENSITIVITY IN B.C.G. INFECTED GUINEAPIGS RELATION TO CORTISONE DESENSITISATION

J. W. CORNFORTH

D. A. LONG

M.Sc. Sydney, D.Phil. Oxf

M.D. Lond.

From the National Institute for Medical Research, Mill Hill,  
London

A.C.T.H. and cortisone depress, and thyroxine increases, hypersensitivity to tuberculin in guineapigs infected with B.C.G. (Long and Miles 1950). But small amounts of thyroxine are needed for desensitisation by the adrenal hormones, which then depress hypersensitivity to the same final level irrespective of the amount of thyroxine available (Long, Miles, and Perry 1951b). The link between this complex interaction of hormones may lie in the metabolism of ascorbic acid; for it is probable that, in the guineapig, the oxidation of ascorbic acid to dehydroascorbic acid initiates desensitisation, and that the thyroid and adrenal hormones exert their influence on the sulphhydryl reducing system responsible for maintaining in the tissues the balance between ascorbic and dehydroascorbic acid (Long, Miles, and Perry 1951a and c, Long 1952). This argument is strengthened by the observation that alloxan, which combines with -SH compounds, diminishes sensitivity

to tuberculin and bears the same relation to dietary and hormonal factors as cortisone (fig. 1) (Long et al. 1951a, b, and c); and also by the fact that the injection of the -SH compound glutathione prevents desensitisation by cortisone (Long et al. 1951c).

In vitro, alloxan inhibits the conversion of glucose-1-phosphate (Cori ester) to glucose-6-phosphate (Robinson ester), the second step in the metabolism of glycogen. This inhibition is attributed to its action as an enzyme destroyer (Lehmann 1939). Alloxan, which has in any case a very short life in the body (Archibald 1945), may not itself exert this influence on the enzyme in vivo, but may do so by inducing overproduction of dehydroascorbic acid, which has already been inferred to be the more immediate agent in alloxan desensitisation (Long et al. 1951c) and which has a chemical structure similar to alloxan. If, then, these speculations are correct, cortisone and alloxan facilitate the formation of dehydroascorbic acid which inactivates phosphoglucomutase and so blocks the conversion of glucose-1-phosphate to glucose-6-phosphate, with accumulation of the former (fig. 2). On the assumption that glucose-1-phosphate represents the next step in the chain of metabolic events leading to diminished sensitivity to tuberculin, it was tested for desensitising power and proved active in a dose of less than 0.025 mg. per kg. body-weight, which is many times less than the minimum effective dose of cortisone, alloxan, or dehydroascorbic acid. Glucose-1-phosphate is of course normally present in the body, but its presence has not to our knowledge been reported in extracellular fluids in vivo. This may account for the effect observed on injection of a dose which must be quite small relative to the body's normal turnover of glucose-1-phosphate. Glucose-6-phosphate, the product formed from glucose-1-phosphate by phosphoglucomutase was also found to desensitise, but the dose required is several hundred times larger than the effective dose of glucose-1-phosphate. This effect may perhaps be due to the equilibrium  $\text{glucose-1-phosphate} \rightleftharpoons \text{glucose-6-phosphate}$ , a large excess of the latter component producing a smaller excess of the former.

In the present paper, the effect on tuberculin sensitivity of glucose-1-phosphate and of other biologically significant phosphorus compounds is compared with that of other desensitising agents—namely, cortisone, alloxan, ascorbic acid and its metabolites (Long 1952), N-acetylsphingosine (Fisher, Harington, and Long 1951), and certain phenolic polyoxyethylene ethers (D'Arcy Hart, Long, and Rees 1952). In addition, the observation that lysergic acid diethylamide, an amide of one of the constituents of ergot, increases, in very small oral doses, the level of hexosemonophosphate in the blood of man, apparently by blocking its further enzymatic breakdown (Mayer-Gross, McAdam, and Walker 1951), provided a second method for testing our hypothesis, since if our speculations are correct, this drug should cause a diminution in sensitivity to tuberculin. It did so, in a dose of less than 0.0002 mg. per kg.

## METHODS AND RESULTS

350 g. albino guineapigs of the Hampstead strain, fed upon a pelleted diet (Bruce and Parkes 1947) supplemented with unlimited cabbage, were injected with B.C.G. vaccine, and sensitivity to tuberculin was estimated by the method of Long and Miles (1950). All drugs tested, with the exception of glutathione, N-acetylsphingosine, and cortisone acetate, were dissolved in 1 ml. of normal saline and injected subcutaneously two hours before the tuberculin.

Phosphates supplied as barium salts were dissolved in saline, treated with a little sodium sulphate, and freed from barium sulphate before injection. Where the substance was given as a salt, the dose has been recalculated to give the amount of organic anion actually present. N-acetylsphingosine and cortisone acetate were suspended in 1 ml.

(R)<sub>6</sub>



According to our hypothesis, the activity of phosphoglucomutase is inhibited by dehydroascorbic acid, with the result that glucose-1-phosphate accumulates



\* Desensitising action prevented by reduced glutathione.  
† Desensitising action not prevented by reduced glutathione.

| Agent and dose per kg. body-weight    | Desensitisation                     |                |
|---------------------------------------|-------------------------------------|----------------|
|                                       | Glutathione<br>(150 mg. per<br>kg.) | No glutathione |
| Alloxan (25 mg.) .. ..                | —                                   | +              |
| Ascorbic acid (50 mg.) .. ..          | —                                   | +              |
| Cortisone acetate (5 mg.) .. ..       | —                                   | +              |
| Dehydroascorbic acid (50 mg.) .. ..   | —                                   | +              |
| Glucose-1-phosphate (12 mg.) .. ..    | +                                   | +              |
| N-acetylsphingosine (30 mg.) .. ..    | +                                   | +              |
| Polyoxyethylene ethers (20 mg.) .. .. | +                                   | +              |

## SUMMARY

2. Injected reduced glutathione prevents the desensitising action of cortisone acetate, alloxan, ascorbic acid, and dehydroascorbic acid, but not of glucose-1-phosphate, N-acetyl-sphingosine and the polyoxyethylene ethers. The

relation of these findings to the mechanism of cortisone desensitisation are discussed.

Our present hypothesis (see fig. 2) provides what we believe to be a useful, though probably oversimplified, summary of the mechanism of cortisone desensitisation. We suggest that cortisone facilitates the oxidation of ascorbic to dehydroascorbic acid. Dehydroascorbic acid inhibits phosphoglucomutase, and as a result glucose-1-phosphate accumulates in the tissues and is intimately concerned with desensitisation.

We are indebted to Dr. Knud Tolderlund, of the State Serum Institute, Copenhagen, for the B.C.G.; to Mr. P. N. Campbell, PH.D., Prof. F. Dickens, F.R.S., Dr. J. D. Judah, Prof. M. Stacey, F.R.S., and Dr. F. Wrigley, of Roche Products Ltd., for phosphate compounds; to Sir Charles Harington, F.R.S., for the N-acetylsphingosine; to Dr. Wrigley, for the glutathione; and to Messrs. Sandoz Ltd., for the lysergic acid diethylamide. We are grateful to our colleagues, Dr. G.

Popják for advice on various aspects of phosphorus metabolism and for providing many of the drugs, and to Mr. T. S. Work, PH.D., for drawing our attention to the biochemical effects of lysergic acid diethylamide.

It is a pleasure to acknowledge the help of Dr. W. L. M. Perry and Miss M. V. Mussett in the statistical analyses of the large number of experiments on which these observations are based.

#### REFERENCES

- Archibald, R. M. (1945) *J. biol. Chem.* **158**, 347.  
Bruce, H. M., Parkes, A. S. (1947) *J. Hyg., Camb.* **45**, 70.  
Fisher, N., Harington, C. R., Long, D. A. (1951) *Lancet*, *ii*, 522.  
Hart, P. D'Arcy, Long, D. A., Rees, R. J. W. (1952) *Brit. med. J.* *i*, 680.  
Lehmann, H. (1939) *Biochem. J.* **33**, 1241.  
Long, D. A. (1952) *Bull. Schweiz Akad. med. Wiss.* **8**, 194.  
— Miles, A. A. (1950) *Lancet*, *i*, 492.  
— — Perry, W. L. M. (1951a) *Ibid.*, *i*, 1085.  
— — — (1951b) *Ibid.*, *p.* 1392.  
— — — (1951c) *Ibid.*, *ii*, 902.  
Mayer-Gross, W., McAdam, W., Walker, J. W. (1951) *Nature, Lond.* **168**, 827.